The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma
- Journal:
- Science Translational Medicine
- Published:
- Affiliations:
- 5
- Authors:
- 29
| Institutions | Authors | Share |
|---|---|---|
| Regeneron Pharmaceuticals, United States of America (USA) | 0.86 | |
| Manchester University NHS Foundation Trust (MFT), United Kingdom (UK) | 0.03 | |
| Medetect, Sweden | 0.03 | |
| Lund University (LU), Sweden | 0.03 | |
| Sanofi, France | 0.03 |